A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 15
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : pVL
Long Form : plasma HIV-RNA
No. Year Title Co-occurring Abbreviation
2019 "Real life" use of raltegravir during pregnancy in France: The Coferal-IMEA048 cohort study. cART, RAL
2018 First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). ART, HIV-2, IQR, PCR, uspVL
2016 Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600mg in Treatment-Naive HIV-Infected Patients at 96Weeks: Results of the ENCORE1 Study. CI, EFV400, OR, PK, SNP
2015 Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. HIV-2, IQR, NPP
2015 Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naive HIV-Infected Patients: Results of the ENCORE1 Study. EFV400
2014 Comparison of central and local HIV-1 RNA quantification from two international clinical trials. ---
2010 Transient lowering of the viral set point after temporary antiretroviral therapy of primary HIV type 1 infection. PHI
2008 Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial. ARV, NNRTI, NRTI
2007 Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. CI
10  2007 Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. IVIG
11  2006 Viral dynamics after starting first-line HAART in HIV-1-infected children. ---
12  2005 Low trough plasma concentrations of nevirapine associated with virologic rebounds in HIV-infected patients who switched from protease inhibitors. NNRTI, PIs
13  2005 Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy. ART, CI, EFV, NVP, VDc
14  2002 A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). ITT
15  1999 Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients. ---